Clinical trials: Rectal Cancer, Radiotherapy
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Rectal Cancer, Locally Advanced
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
The goal of this phase 2 study is to learn about the efficacy and safety of short-course radiotherapy (SCRT) sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable (MSS) locally…
- Trial name
- SPARC (NCT05576480)
- Testing
- Short-course radiotherapy, Penpulimab, CAPEOX
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Colon Cancer, Rectal Cancer
Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer
Patients with oligometastatic colorectal cancer (5 metastases or less) receive a combination of systemic treatment and often local treatment, such as surgery, radiofrequency ablation and more recently stereotactic body…
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer
- Trial name
- tomoligo (NCT00807313)
- Where
- Belgium
- Volunteers
- 53 people
- Sponsor
- Universitair Ziekenhuis Brussel
Rectal Cancer
MMP-7 Modulation by Short and Long Term Radiotherapy in Rectal Cancer Patients
To analyse the effects of radiation therapy on inflammation and matrilysin levels in rectal cancer patients.
- Trial name
- MMP-7 (NCT03151759)
- Testing
- Neoadjuvant radiotherapy
- Volunteers
- 77 people
- Sponsor
- Region Skane
Rectal Cancer
Tecemotide (L-BLP25) in Rectal Cancer
The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25) administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects with newly diagnosed rectal cancer who are…
- Trial name
- SPRINT (NCT01507103)
- Testing
- Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Anal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003652
- Testing
- cisplatin, fluorouracil, neoadjuvant therapy
- Where
- 48 sites in France
- Volunteers
- 350 people
- Sponsor
- UNICANCER
Rectal Cancer
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.
Background The current management on rectal cancer based on TNM staging has some limitations. In locally advanced rectal cancer after neoadjuvant therapy the persistence of a complete response to therapy cannot be accurately…
- Trial name
- IMMUNOREACT2 (NCT04917263)
- Testing
- Immunohistochemistry, Flow citometry, Trascriptome analysis
- Where
- Italy
- Volunteers
- 544 people
- Sponsor
- University of Padova
Breast Cancer, Lung Cancer
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients
The purpose of this study is to evaluate the effectiveness and feasibility of the Screening Inventory of Psychosocial Problems (SIPP) in consultation settings with respect to early recognition and treatment of psychosocial…
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer
- Trial name
- NCT00859768
- Testing
- Questionnaire administration
- Where
- Netherlands
- Volunteers
- 568 people
- Sponsor
- Netherlands Open University
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
This phase 1b trial studies the side effects and best dose of TAS-102 when given together with radiation therapy in treating patients with stage II-III rectal cancer that has not been treated and can be removed by surgery…
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04104139
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Locally Advanced Rectal Cancer
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This study will evaluate the efficacy and safety of SHR-1701 combined with radiotherapy and chemotherapy as perioperative treatment for locally advanced rectal cancer.
- Trial name
- NCT05300269
- Testing
- SHR-1701；Capecitabine；Oxaliplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Rectal Cancer
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of…
- Trial name
- NCT01749956
- Testing
- Radiation, Aflibercept, Surgery
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- SCRI Development Innovations, LLC
Chronic Radiation-induced Proctitis
KANGFUPEN Liquid Dressing for Chronic Radiation-Induced Rectal Injury
This clinical trial aims to evaluate the efficacy and safety of Kangfupen (a topical liquid dressing) in treating chronic radiation-induced proctitis (RTOG Grade 2 or higher). The key questions we aim to answer are: 1.
- Trial name
- NCT07065175
- Testing
- Kangfupen (liquid dressing) retention enema administration
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Colorectal Cancer (CRC), mCRC
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
This is a randomized, parallel, open-label, multicenter exploratory clinical study designed to investigate the efficacy and safety of iparomlimab and tuvonralimab in combination with fruquintinib plus heterogeneous radiotherapy…
- Trial name
- NCT07502014
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Fruquintinib, Heterogeneous Radiotherapy
- Volunteers
- 60 people
- Sponsor
- Huazhong University of Science and Technology
Rectal Neoplasms
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
The investigators propose to conduct a randomised study on cT2, cT3a-b tumours less than 5 cm using two different techniques of radiotherapy boost following neoadjuvant chemoradiotherapy (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or…
- Trial name
- OPERA (NCT02505750)
- Testing
- 3D conformal EBRT, Contact X-ray brachytherapy 50 kV, Capecitabine
- Where
- 18 sites in France, Switzerland and 1 more
- Volunteers
- 148 people
- Sponsor
- Centre Antoine Lacassagne
Acute Radiation Enteritis
Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy
Research Objective and Principle: To evaluate the effectiveness of Bergmann enema in preventing acute radiation-induced rectal injury in patients with rectal cancer, thereby providing a basis for treatment options for potential…
- Trial name
- NCT07302126
- Testing
- Bergmann enema
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
TaTME Versus Open Intersphincteric Resection After Neoadjuvant Concurrent Chemoradiotherapy.
The two surgical options for lower 1/3 rectal cancer is APR and sphincter sparing procedures. Intersphincteric resection is procedure to treat very low rectal cancer within 2 cm from the dentate line to avoid permanent…
- Trial name
- TaTME (NCT01836926)
- Testing
- Open intersphincteric resection, transanal minimally invasive intersphincteric resection
- Where
- 2 sites in Egypt
- Volunteers
- 110 people
- Sponsor
- Osama Mohammad Ali ElDamshety
Unresectable Metastatic Rectal Cancer, CAPOX
Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer
To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer
- Conditions
- Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy
- Trial name
- Union-mRC (NCT07059949)
- Testing
- CAPOX+ Camrelizumab+ Cetuximab, CAPOX+ Camrelizumab+ Bevacizumab
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Rectal Cancer
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
The purpose of this study is to explore the efficacy and safety of involved-field radiotherapy-TNT combined with PD-1 inhibitors in pMMR locally advanced rectal cancer.
- Trial name
- NCT07057089
- Testing
- Capecitabine, Camrelizumab, CAPOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hebei Medical University Fourth Hospital
Rectal Cancer
Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)
To investigate a potential toxicity benefit of preoperative radiation therapy with protons compared to conventional photon beam radiation therapy in patients with locally advanced rectal cancer.
- Trial name
- PRORECT (NCT04525989)
- Testing
- Radiation therapy
- Where
- 9 sites in Sweden
- Volunteers
- 254 people
- Sponsor
- Alexander Valdman
Rectal Cancer
Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma
This phase III trial included patients with low rectal adenocarcinoma which initially required APR, with a mean clinical distance between the tumor inferior pole and the levator ani of 0.5 cm.
- Trial name
- GRECCAR1 (NCT00979680)
- Testing
- High-Dose radiotherapy, Chemo-radiotherapy
- Where
- 12 sites in France
- Volunteers
- 207 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle